Wade T. Iams, MD

Wade T. Iams, MD

Wade Iams, MD, is the director of Lung Cancer Research at Tennessee Oncology in Nashville.

Articles by Wade T. Iams, MD

Wade Iams, MD, MSCI, of Tennessee Oncology, explains how his team keeps patients on prophylactic strategies when starting subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer: repeated touches from multiple members of the care team over time, including his own counseling, nursing education at the injection visit, a call from a specialty pharmacist for the oral agent, and follow-up by advanced practice providers.

Wade Iams, MD, MSCI, of Tennessee Oncology, describes how he opens the first treatment conversation with patients who have EGFR-mutated advanced non–small cell lung cancer and with their families, after Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, notes that grade 3 or higher adverse events were more common with amivantamab plus lazertinib than with osimertinib in MARIPOSA.

2 experts are featured in this series

Panelists discuss how CA-LEMS biology reflects an off-target antitumor immune response (often with SCLC) that generates antibodies against presynaptic VGCCs, reducing acetylcholine release and causing proximal weakness with brief strength improvement after repeated activation.

6 experts in this video

Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.

Latest Updated Articles